

---

# How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD Guidance for Industry

## ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Elizabeth Giaquinto 240-402-7930.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**December 2014  
Generics**

# How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD Guidance for Industry

*Additional copies are available from:  
Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10001 New Hampshire Ave., Hillandale Bldg., 4<sup>th</sup> Floor  
Silver Spring, MD 20993  
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353  
Email: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)  
<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**December 2014  
Generics**

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION</b> .....	<b>1</b>
<b>II.</b>	<b>BACKGROUND</b> .....	<b>1</b>
<b>A.</b>	<b>ANDAs</b> .....	<b>1</b>
<b>B.</b>	<b>REMS</b> .....	<b>2</b>
<b>III.</b>	<b>PROCEDURES FOR SUBMISSION AND REVIEW OF BIOEQUIVALENCE PROTOCOLS FOR DRUG PRODUCTS WITH REMS ETASU</b> .....	<b>3</b>
<b>A.</b>	<b>Submission</b> .....	<b>3</b>
<b>B.</b>	<b>FDA Review</b> .....	<b>3</b>
	<b>APPENDIX</b> .....	<b>5</b>

1           **How to Obtain a Letter from FDA Stating that Bioequivalence**  
2           **Study Protocols Contain Safety Protections Comparable to**  
3           **Applicable REMS for RLD**  
4           **Guidance for Industry<sup>1</sup>**  
5

6  
7 This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current  
8 thinking on this topic. It does not create or confer any rights for or on any person and does not operate to  
9 bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of  
10 the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA  
11 staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call  
12 the appropriate number listed on the title page of this guidance.  
13

14  
15  
16  
17 **I. INTRODUCTION**  
18

19 This guidance describes how a prospective abbreviated new drug application (ANDA) applicant  
20 may request a letter stating that FDA has determined: (1) that the prospective applicant's  
21 bioequivalence (BE) study protocol contains safety protections comparable to those in the risk  
22 evaluation and mitigation strategy (REMS) with elements to assure safe use (ETASU) applicable  
23 to the reference listed drug (RLD), and (2) that FDA will not consider it a violation of the REMS  
24 for the RLD sponsor to provide a sufficient quantity of the RLD to the interested generic firm or  
25 its agent to allow the firm to perform the testing necessary to support its ANDA.  
26

27 FDA's guidance documents, including this guidance, do not establish legally enforceable  
28 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should  
29 be viewed only as recommendations, unless specific regulatory or statutory requirements are  
30 cited. The use of the word *should* in Agency guidances means that something is suggested or  
31 recommended, but not required.  
32

33 **II. BACKGROUND**  
34

35 **A. ANDAs**  
36

37 The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman  
38 Amendments) created section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)  
39 (21 U.S.C. 355(j)), which established the current ANDA approval process. To obtain approval  
40 to market a generic drug, an ANDA applicant is not required to submit clinical studies to  
41 establish the safety and effectiveness of the proposed generic drug product, but instead may rely

---

<sup>1</sup> This guidance has been prepared by the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

42 on the Agency’s previous finding of safety and effectiveness for the RLD. To do so, an ANDA  
43 applicant generally must demonstrate that its drug product is bioequivalent to, and has the same  
44 active ingredient, dosage form, route of administration, strength, labeling, and conditions of use  
45 as, the RLD (FD&C Act, section 505(j)(2)(A)).

46  
47 BE is generally demonstrated via BE studies in which the proposed generic product is compared  
48 to the RLD. These studies require that the ANDA applicant has access to a sufficient quantity of  
49 the RLD to conduct the necessary comparisons between its test product and the RLD. Other  
50 testing (such as that necessary to establish the appropriate dissolution specifications for the  
51 proposed generic product) and/or regulatory requirements (such as those relating to the retention  
52 of reserve samples) may require the ANDA applicant to obtain additional supplies of the RLD.

### **B. REMS**

54  
55  
56 Section 505-1(a)(1) of the FD&C Act authorizes FDA to require applicants to submit a proposed  
57 REMS as a part of the relevant application<sup>2</sup> if FDA determines that a REMS is necessary to  
58 ensure that the benefits of a drug outweigh its risks (21 U.S.C. 355-1(a)(1)). A REMS is a  
59 required risk management plan that uses tools beyond routine professional labeling (such as a  
60 medication guide, a patient package insert, and/or a communication plan) to ensure that the  
61 benefits of a drug outweigh its risks (FD&C Act, section 505-1(f)). In addition, FDA may  
62 require ETASU in some circumstances when such elements are necessary to mitigate the risks  
63 associated with the drug. ETASU may include, for example, requirements that health care  
64 providers who prescribe or administer the drug have particular training or certification, that  
65 patients using the drug be monitored and/or enrolled in a registry, or that pharmacies,  
66 practitioners, or health care settings that dispense the drug be specially certified.

67  
68 FDA is aware of instances in which an RLD sponsor has refused to sell drug product to a  
69 prospective ANDA applicant seeking to conduct the testing needed to obtain approval, and the  
70 RLD sponsor has cited the REMS ETASU as justification. In the interest of facilitating  
71 prospective generic applicants’ access to RLD supplies to conduct the testing necessary to  
72 support ANDA approval, FDA has, on request, reviewed the BE study protocols proposed by  
73 prospective ANDA applicants to assess whether they provide safety protections comparable to  
74 those in the applicable REMS ETASU. When the Agency has determined that comparable  
75 protections existed, FDA has issued letters to the RLD sponsors stating so and indicating that  
76 FDA would not consider it to be a violation of the REMS for the RLD sponsor to provide drug  
77 product to the prospective ANDA applicant.

78  
79 Requesting or obtaining such a letter from FDA is not a legal requirement. If a prospective  
80 ANDA applicant chooses to request such a letter, this guidance is intended to clarify the process  
81 for doing so.

---

<sup>2</sup> Section 505-1 of the FD&C Act applies to any application for approval of a prescription drug submitted under sections 505(b) or (j) of the FD&C Act (including both NDAs submitted under section 505(b)(2) and ANDAs submitted under section 505(j)), as well as applications submitted under section 351 of the Public Health Service Act (42 U.S.C. 262).

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123

### **III. PROCEDURES FOR SUBMISSION AND REVIEW OF BIOEQUIVALENCE PROTOCOLS FOR DRUG PRODUCTS WITH REMS ETASU**

#### **A. Submission**

- The prospective ANDA applicant should check the Agency’s online listing of approved REMS<sup>3</sup> to determine whether the proposed RLD is subject to an approved REMS with ETASU. Study protocols for drugs not subject to approved REMS with ETASU should not be submitted to FDA for purposes of this guidance.
- If the proposed RLD is a drug product that is subject to an approved REMS with ETASU, the prospective ANDA applicant should prepare one or more (as necessary) complete BE protocol(s) that incorporate the elements of the RLD’s labeling and ETASU that are necessary to conduct the BE study (or studies) in a safe manner. For example, if the applicable REMS is designed to prevent fetal exposure to a drug, then the BE protocol should protect against pregnancy in a manner comparable to what is provided for in the REMS.
- The prospective ANDA applicant may submit to [GenericDrugs@fda.hhs.gov](mailto:GenericDrugs@fda.hhs.gov) the draft BE protocol(s), all informed consent documents, and all informational materials that will be distributed to the study investigators, pharmacists, and subjects. Electronic submissions are strongly preferred.

#### **B. FDA Review**

- The Office of Generic Drugs’ (OGD) Office of Bioequivalence’s Division of Bioequivalence (DBE) and Division of Clinical Review (DCR) will review the draft BE protocol(s), informed consent document(s), and informational materials submitted. Others within the Agency may be consulted as necessary. Any concerns identified during this review will be communicated in a letter to the prospective ANDA applicant along with recommended changes.
- If there are recommended changes, the prospective ANDA applicant should revise the BE protocol(s), informed consent documents, and/or informational materials as appropriate and submit them to DBE and DCR for review. Electronic submissions are strongly preferred.
- If FDA determines that the protocols, informed consent documents, and informational materials contain safety protections comparable to those in the REMS ETASU, OGD will notify the prospective ANDA applicant in a letter that this determination has been made. This letter will advise the prospective ANDA applicant to provide a completed disclosure

---

<sup>3</sup> See Approved Risk Evaluation and Mitigation Strategies (REMS): [www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm).

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

124 authorization form (see Appendix) if they wish to have FDA issue a letter to the RLD  
125 sponsor, and will request that the prospective ANDA applicant provide FDA with the  
126 quantity of drug product per strength necessary to support its ANDA.  
127

128 • At the prospective ANDA applicant's request, FDA will send a letter to the RLD sponsor  
129 stating that:

130

- 131 ○ The Agency has determined that the protocols, informed consent documents, and  
132 informational materials contain safety protections comparable to those in the  
133 applicable REMS ETASU.

- 134 ○ FDA will not consider it a violation of REMS for the RLD sponsor to provide the  
135 designated potential ANDA applicant (or its agent) a sufficient quantity of drug  
136 product to allow it to perform the testing necessary to support its ANDA and  
137 otherwise meet the requirements for ANDA approval.  
138

139  
140

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

141  
142  
  
143  
  
144  
145  
146  
147  
148  
149  
150  
151  
152  
  
153  
154  
155  
156  
157  
158  
  
159  
160  
161  
162  
163  
  
164  
  
165  
  
166  
  
167  
  
168  
  
169  
  
170  
171  
172

**APPENDIX**

Dear **[insert name of Director, Office of Generic Drugs]**:

On behalf of **[insert name of prospective ANDA applicant]**, I authorize the United States Food and Drug Administration (FDA) to disclose the information described below to **[insert name of RLD holder]**. I understand that the information that is disclosed may contain confidential commercial or financial information or trade secrets within the meaning of 18 U.S.C. § 1905, 21 U.S.C. § 331(j), and 5 U.S.C. § 552(b)(4) that is exempt from public disclosure under those statutory provisions and/or relevant FDA regulations. I acknowledge that once this information is shared with **[insert name of RLD holder]**, it may not be subject to the same protections from disclosure that would otherwise be applicable. I agree to hold FDA harmless for any injury caused by FDA's sharing the information.

Information to be shared: FDA has received a request from **[insert name of prospective ANDA applicant]** for assistance in obtaining supplies of **[insert name of drug product]** for the purpose of testing a proposed generic **[active ingredient]** product against **[brand drug name]** as the reference listed drug. **[Insert name of prospective ANDA applicant]** has submitted for FDA's review study protocols that include safety precautions for testing comparable to those set forth in the FDA-mandated REMS for **[brand drug name]**.

Authorization is given to FDA to disclose the above-mentioned information which may include confidential commercial or financial information or trade secrets. As indicated by my signature, I am authorized to provide this consent on behalf of **[insert name of prospective ANDA applicant]** and my full name, title, address, telephone number, and facsimile number are set out below for verification.

Sincerely,  
  
(Signature)  
  
(Printed name)  
  
(Title)  
  
(Telephone & Facsimile Numbers)